Austrian Breast & Colorectal Cancer Study Group

Science from the heart of Europe

ABCSG 61 / TEODOR: First Patient Registered in the Run-in Phase

The ABCSG is pleased to announce another important milestone in the national phase II study ABCSG 61 / TEODOR (Neoadjuvant TrEatment Optimization driven by ctDNA and endOcrine Responsiveness). Under the coordination of Dr. Daniel Egle, the first patient was registered in the run-in phase at the Breast Health Center of the Department of Obstetrics and Gynecology at the Medical University of Innsbruck.

ABCSG 61 / TEODOR is a prospective, randomized, controlled, open-label multicenter phase II study investigating neoadjuvant endocrine therapy versus chemotherapy in HR-positive, HER2-negative, ctDNA-negative and endocrine responsive early and locally advanced breast cancer.

A total of 14 Austrian centers will participate in the study, with a planned enrollment of 256 patients.

We cordially congratulate the entire Innsbruck team on this important milestone and look forward to continued successful collaboration!

→ Further Information

More posts on the topic:
ABCSG 61

• ABCSG 61 / TEODOR: First center opened for patient enrollment

Share on